Archive | GlycoMimetics

GlycoMimetics CEO Rachel King Included Among I95 BUSINESS’ Six Powerful Women Leaders in Life Sciences

Rachel 2018-09-28 Glycomimetics retouch-2-2

Editor’s Note: The Mid-Atlantic region is chocked full of high-profile health care companies that call Maryland home. Many of them are led by brilliant, innovative leaders who just happen to also be women.  Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc. Rachel K. King co-founded GlycoMimetics, Inc. (GMI) in 2003 and has served as its CEO […]

Comments Off on GlycoMimetics CEO Rachel King Included Among I95 BUSINESS’ Six Powerful Women Leaders in Life Sciences Continue Reading →

GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer

2019-08-01 Glycomimetics-106_eric feldman

ROCKVILLE, Md.–(BUSINESS WIRE)–Feb. 23, 2021– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development. “Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone […]

Comments Off on GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer Continue Reading →

GlycoMimetics CEO Rachel King Featured in “Her Story” Podcast Along with BIO’s Dr. Michelle McMurry-Heath

Rachel 2018-09-28 Glycomimetics retouch-2-2

In this conversation, Ms. King and Dr. McMurry-Heath share stories underlying their careers in scientific innovation, from the lab bench to government, consulting, and venture capital; and their experiences as one of the few women CEOs in biotechnology.

Comments Off on GlycoMimetics CEO Rachel King Featured in “Her Story” Podcast Along with BIO’s Dr. Michelle McMurry-Heath Continue Reading →

FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease

logo-glyco

ROCKVILLE, Md.–(BUSINESS WIRE)–Oct. 5, 2020– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of sickle cell disease in patients 18 years old and younger. This designation recognizes the significant needs in pediatric patients. “The FDA’s designation recognizes the morbidity […]

Comments Off on FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease Continue Reading →

Life Science Leader — Leading Through Adversity: A CEO Roundtable on Drug Development During a Pandemic

lifescileader

Four biopharma CEOs discuss with Rob Wright, chief editor of Life Science Leader, how they are leading their organizations and conducting drug development during the COVID-19 pandemic. Appearing in this video are: Jeremy Levin, DPhil, MB, BChir, CEO of Ovid TherapeuticsGil Van Bokkelen, Ph.D., chairman and CEO of AthersysRachel King, CEO, GlycoMimeticsTed Love, M.D., President […]

Comments Off on Life Science Leader — Leading Through Adversity: A CEO Roundtable on Drug Development During a Pandemic Continue Reading →

BioBuzz: Rachel King of GlycoMimetics Among 12 Women Who Have Shaped the History of the BioHealth Capital Region

Rachel 2018-09-28 Glycomimetics retouch-2-2

The BioHealth Capital Region (BHCR) and its life science ecosystem have a rich and deep history of pioneering scientific innovation, research, development, and commercialization. The region’s history has been written by life science anchor companies, scientific research universities, government research organizations, rich startup culture, and serial entrepreneurs, all of whom have played critical roles in […]

Comments Off on BioBuzz: Rachel King of GlycoMimetics Among 12 Women Who Have Shaped the History of the BioHealth Capital Region Continue Reading →

Washington Business Journal: Maryland Biotech Outlines Path for Blood Cancer Drug, Including in China

logo-glyco

Rockville biotech GlycoMimetics Inc. has entered into a license agreement worth $189 million or more with a West Coast company. The deal gives cancer therapy biopharma Apollomics Inc. of Foster City, California exclusive rights to develop and commercialize GlycoMimetics’ blood cancer drug in greater China, which encompasses mainland China, Hong Kong, Taiwan and Macau, the […]

Comments Off on Washington Business Journal: Maryland Biotech Outlines Path for Blood Cancer Drug, Including in China Continue Reading →

GlycoMimetics CEO Rachel King Featured in Article on Uproleselan

RachelKing

In Cancer, Boosting Chemotherapy while Reducing Toxic Side Effects is a Potential Breakthrough GlycoMimetics is conducting a pivotal Phase 3 trial in the US, Europe and Australia to determine if its drug candidate, uproleselan, can successfully treat patients with relapsed and refractory acute myeloid leukemia (AML), a blood cancer. The unique aspect of uproleselan is […]

Comments Off on GlycoMimetics CEO Rachel King Featured in Article on Uproleselan Continue Reading →

GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel

logo-glyco

ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 29, 2019– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and […]

Comments Off on GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel Continue Reading →